Peginterferon and ribavirin for chronic hepatitis C

New England Journal of Medicine

Volumn 355, Issue 23, 2006, Pages 2444-2451

  Hoofnagle, Jay H ^a,b   Seeff, Leonard B ^a  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALKALINE PHOSPHATASE; ALPHA INTERFERON; BILIRUBIN; PEGINTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PROTHROMBIN; RIBASPHERE; RIBAVIRIN; VIRUS RNA;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANXIETY DISORDER; ARTICLE; BLOOD CELL COUNT; CLINICAL TRIAL; CONCENTRATION LOSS; DEPRESSION; DRUG COST; DRUG DOSE REDUCTION; DRUG HALF LIFE; DRUG MECHANISM; DRUG WITHDRAWAL; FATIGUE; HEART INFARCTION; HEMOLYSIS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IRRITABILITY; LABORATORY TEST; LIVER BIOPSY; LIVER FIBROSIS; MYALGIA; NONHUMAN; PATHOPHYSIOLOGY; PHYSICAL EXAMINATION; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; SIDE EFFECT; SLEEP DISORDER; STROKE;

ADULT; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; POLYETHYLENE GLYCOLS; PRACTICE GUIDELINES; RIBAVIRIN; RNA, VIRAL;

EID: 33845449051     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMct061675     Document Type: Article

References (50)

1. Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med 2001;345:41-52.
2. Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 2006;144:705-14.
3. Wasley A, Alter MJ. Epidemiology of hepatitis C: geographic differences and temporal trends. Semin Liver Dis 2000;20:1-16.
4. Armstrong GL, Alter MJ, McQuillan GK, Margolis HS. The past incidence of hepatitis C virus infection: implications for the future burden of chronic liver disease in the United States. Hepatology 2000;31:777-82.
5. Thomas DL, Seeff LB. Natural history of hepatitis C. Clin Liver Dis 2005;9:383-98.
6. Fattovich G, Stoffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 2004;127:Suppl 1:S35-S50.
7. Lindenbach BD, Rice C. Unraveling hepatitis C virus replication from genome to function. Nature 2005;436:933-8.
8. Neumann AU, Lam NP, Dahari H, et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 1998;282:103-7.
9. Simmonds P, Bukh J, Combet C, et al. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology 2005;42:962-73.
10. Hoofnagle JH. Course and outcome of hepatitis C. Hepatology 2002;36:Suppl 1:S21-S29.
11. Rehermann B, Nascimbeni M. Immunology of hepatitis B virus and hepatitis C virus infection. Nat Rev Immunol 2005;5:215-29.
12. Bowen DG, Walker CM. Adaptive immune responses in acute and chronic hepatitis C virus infection. Nature 2005;436:946-52.
13. National Institutes of Health Consensus Development Conference Statement: management of hepatitis C: 2002 - June 10-12, 2002. Hepatology 2002;36:Suppl 1:S3-S20.
14. Feld JJ, Hoofnagle JH. Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature 2005;436:967-72.
15. Sen GC. Viruses and interferons. Annu Rev Microbiol 2001;55:255-81.
16. Tilg H. New insights into the mechanisms of interferon α: an immunoregulatory and anti-inflammatory cytokine. Gastroenterology 1997;112:1017-21.
17. Lau JY, Tam RC, Liang TJ, Hong Z. Mechanism of action of ribavirin in the combination treatment of chronic HCV infection. Hepatology 2002;35:1002-9.
18. Maag D, Castro C, Hong Z, Cameron CE. Hepatitis C virus RNA-dependent RNA polymerase (NS5B) as a mediator of the antiviral activity of ribavirin. J Biol Chem 2001;276:46094-8.
19. Crotty S, Maag D, Arnold JJ, et al. The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen. Nat Med 2000;6:1375-9. [Erratum, Nat Med 2001;7:255.]
20. Myers RP, Regimbeau C, Thevenot T, et al. Interferon for interferon naïve patients with chronic hepatitis C. Cochrane Database Syst Rev 2002;2:CD000370.
21. McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998;339:1485-92.
22. Poynard T, Marcelllin P, Lee SS, et al. Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 1998;352:1426-32.
23. Brok J, Gluud LL, Gluud C. Ribavirin monotherapy for chronic hepatitis C infection: a Cochrane Hepato-Biliary Group systematic review and meta-analysis of randomized trials. Am J Gastroenterol 2006;101:842-7.
24. Glue P, Fang JWS, Rouzier-Panis R, et al. Pegylated interferon-α2b: pharmacokinetics, pharmacodynamics, safety and preliminary efficacy data. Clin Pharmacol Ther 2000;68:556-67.
25. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358:958-65.
26. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-82.
27. Hadziyannis SJ, Sette H Jr, Morgan TR, et al. Peginterferon alfa-2a and ribavirin combination therapy in chronic hepatitis C: randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004;140:346-55.
28. Strader DB, Wright T, Thomas DL, Seeff LB, American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C. Hepatology 2004;39:1147-71. [Erratum, Hepatology 2004;40:269.]
29. Dienstag JL, McHutchison JG. American Gastroenterological Association technical review on the management of hepatitis C. Gastroenterology 2006;130:231-64.
30. Chevaliez S, Pawlotsky JM. Use of virologic assays in the diagnosis and management of hepatitis C virus infection. Clin Liver Dis 2005;9:371-82.
31. Bacon BR. Treatment of patients with hepatitis C and normal serum aminotransferase levels. Hepatology 2002;36:Suppl 1:S179-S184.
32. Kleiner DE. The liver biopsy in chronic hepatitis C: a view from the other side of the microscope. Semin Liver Dis 2005;25:52-64.
33. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. Hepatology 1996;24:289-93.
34. Ishak K, Baptista A, Bianchi L, et al. Histologic grading and staging of chronic hepatitis. J Hepatol 1995;22:696-9.
35. Bedossa P, Dargere D, Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology 2003;38:1449-57.
36. Graham CS, Baden LR, Yu E, et al. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. Clin Infect Dis 2001;33:562-9.
37. Thomas DL. Hepatitis C and human immunodeficiency virus infection. Hepatology 2002;36:Suppl 1:S201-S209.
38. Zeuzem S, Buti M, Ferenci P, et al. Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. J Hepatol 2006;44:97-103.
39. Dalgard O, Bjoro K, Hellum KB, et al. Treatment with pegylated interferon and ribavirin in HCV infection with genotype 2 or 3 for 14 weeks: a pilot study. Hepatology 2004;40:1260-5.
40. Mangia A, Santoro R, Minerva N, et al. Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. N Engl J Med 2005;352:2609-17.
41. von Wagner M, Huber M, Berg T, et al. Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. Gastroenterology 2005;129:522-7.
42. El-Zayadi AR, Attia M, Barakat EM, et al. Response of hepatitis C genotype-4 naïve patients to 24 weeks of peginterferon-alpha2b/ribavirin or induction-dose interferon-alpha2b/ribavirin/amantadine: a non-randomized controlled study. Am J Gastroenterol 2005;100:2447-52.
43. Conjeevaram HS, Fried MW, Jeffers LJ, et al. Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. Gastroenterology 2006;131:470-7.
44. Fried MW. Side effects of therapy of hepatitis C and their management. Hepatology 2002;36:Suppl 1:S237-S244.
45. Wirth S, Pieper-Boustani H, Lang T, et al. Peginterferon alfa-2b plus ribavirin treatment in children and adolescents with chronic hepatitis C. Hepatology 2005;41:1013-8.
46. Jaeckel E, Cornberg M, Wedenmeyer H, et al. Treatment of acute hepatitis C with interferon alfa-2b. N Engl J Med 2001;345:1452-7.
47. Wiegand J, Buggisch P, Boecher W, et al. Early monotherapy with pegylated interferon alfa-2b for acute hepatitits C infection: the HEP-NET acute-HCV-II study. Hepatology 2006;43:250-6.
48. McHutchison JG, Manns M, Patel K, et al. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 2002;123:1061-9.
49. Davis GL. Monitoring of viral levels during therapy of hepatitis C. Hepatology 2002;36:Suppl 1:S145-S151.
50. McHutchison JG, Bartenschlager R, Patel K, Pawlotsky JM. The face of future hepatitis C drug development: recent biological and virological advances and their translation to drug development and clinical practice. J Hepatol 2006;44:411-21.